Enter multiple symbols separated by commas

Search results for "AVIV"



About 29 results. Sort By: Date | Relevance
Radware misses Street 2Q forecasts

TEL AVIV, Israel _ Radware Ltd. on Tuesday reported second-quarter profit of $7.2 million. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 24 cents per share. Radware shares have fallen roughly 9 percent since the beginning of the year.
Source: The Associated Press
Dow closes near 6-month low amid China, commodity slide

U.S. stocks closed lower under pressure from an overnight plunge in the Shanghai Composite and a continued decline in commodities.
Source: CNBC.com | By: Evelyn Cheng
UPDATE 3-Teva to buy Allergan generic drug business for $40.5 bln, drops Mylan bid

TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms. It also will allow Dublin- based Allergan, the third-largest generic drugmaker in the United States, to focus on branded drugs...
Source: Reuters | By: Tova Cohen and Steven Scheer
Early movers: AGN, MYL, MHFI, UBS, FCAU & more

These are the stocks posting the largest moves before the bell.
Source: CNBC.com | By: Peter Schacknow
Teva to buy Allergan's generics business for $40.5B

Israel's Teva Pharmaceutical will buy Allergan's generic pharmaceuticals business for $40.5 billion.
Source: CNBC.com | By: Tom DiChristopher
UPDATE 2-Teva to buy Allergan generic drug business for $40.5 bln

TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a deal that will turn Teva into one of the top 10 pharmaceutical companies. Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and...
Source: Reuters | By: Tova Cohen
Israel's Teva buys Allergan generic drug company for $40.5B

JERUSALEM- Israel's Teva Pharmaceutical Industries Ltd. said Monday it is purchasing Dublin- based Allergan PLC's generic pharmaceuticals business for $40.5 billion, in what Israeli analysts called the largest-ever acquisition by an Israeli company. Statements from both companies say the deal will see Allergan receive $33.75 billion in cash and shares...
Source: The Associated Press
Allergan buys Naurex for $560M as deal talk swirls

Allergan is considering a breakup of the company into two businesses, a person familiar with the matter told Reuters on Friday.
Source: Reuters
Facebook partnership a boon for video technology firm Bidalgo

TEL AVIV, July 26- Facebook marketing partner Bidalgo targets a tripling in sales in 2015 as its new technology to automate the process of making personalised online video advertising benefits from Facebook's growing share of the video market. Facebook is becoming a leader in the video market as users prefer to watch video ads over static images, said Peleg...
Source: Reuters | By: Tova Cohen
Allergan bid may be healthier for Teva than battle with Mylan

TEL AVIV, July 26- After months of sparring in a hostile takeover bid for rival Mylan NV, Teva Pharmaceutical's move to buy Allergan Plc's generic drug business instead could be a smoother ride that will bring bigger returns, faster. Israel- based Teva, the world's largest generic drugmaker, is in advanced talks to buy Allergan's generic drugs unit for between $40-...
Source: Reuters | By: Tova Cohen and Ari Rabinovitch